Savior Lifetec (4167) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Savior Lifetec stock TWD 9.26, price TWD 18.40, that is 49.7% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 12.68 TWD – 94.05 TWD · fair‑value band 7.82 TWD – 11.69 TWD · the 18.40 TWD price screens above the 9.26 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.
Follow Savior Lifetec in your weekly email
Every Wednesday you see whether Savior Lifetec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally.
Show moreShow less
The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services.
In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.
Stock analysis
Savior Lifetec (4167) currently trades at 18.40 TWD, while our model-based Fair Value estimate is 9.26 TWD, 50% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 26.93 TWD per share, and 3 of the 15 models we run sit above the 18.40 TWD price.
Bear case: the Dividend Discount group reads lowest at 3.17 TWD, and 12 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 7.82 TWD (bear) to 11.69 TWD (bull), the price of 18.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Savior Lifetec reported revenue of 1.2B TWD in FY2025 versus 1.7B TWD in FY2021, a compound −8.9%/yr. Reported net income was 537M TWD in FY2025.
Key figures
Market cap 6.1B TWD (≈ $185M) Micro · P/E ratio 6.3 · P/S ratio 5.43 · EPS (TTM) 2.93 TWD · Dividend yield 4.1% · Net margin 91.9% · Return on equity 25.7% · Return on assets (EBIT) 1.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −50%, 4167 screens richer than that median.
Fair Value models
Bear7.82 TWDFair Value 9.26 TWDBull11.69 TWD
Price 18.40 TWD · Downside -49.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.87 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Start year 2020 (pandemic). Over 10 years: +0.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +22.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.4%
Dividend (yield on the price)4.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 17%
⚠ Revenue per share shrinking 3.8%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Approximate: the rate leans on 2025, which sits 1,852% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−49.7% · Below median
Profitability
Return on equity (12 months)25.7% · Top 25%
Return on assets12.8% · Top 25%
Net margin (12 months)91.9% · Top 25%
Operating margin (12 months)5.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)−14.8% · Bottom 25%
Dividend yield (12 months)4.1% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)6.3× · Cheapest 25%
P/B1.61× · Cheaper than median
P/S (12 months)5.43× · Cheaper than median
EV/EBITDA29.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)82· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Savior Lifetec Fair Value". https://www.fairvalue-calculator.com/stock/4167
Frequently asked questions
Is Savior Lifetec (4167) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 9.26 TWD versus a price of 18.40 TWD, about 50% lower (overvalued).
What is the fair value of 4167?
Our model-based fair value for Savior Lifetec is 9.26 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 18.40 TWD.
What is the quality score of 4167?
Savior Lifetec has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Savior Lifetec (4167)?
Our model-based price target is the fair value of 9.26 TWD (as of Nov 4, 2026) from 15 valuation models. Cautious scenario 7.82 TWD, optimistic scenario 11.69 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Savior Lifetec stock forecast for 2026?
Our models put fair value at 9.26 TWD, about 50% lower versus a price of 18.40 TWD (overvalued). Cautious scenario 7.82 TWD, optimistic scenario 11.69 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Savior Lifetec (4167)?
Savior Lifetec reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Nov 4, 2026).
Does Savior Lifetec pay a dividend?
Savior Lifetec currently shows a dividend yield of 4.09% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Savior Lifetec (4167) and when is the ex-dividend date?
Savior Lifetec pays a dividend of 0.753 TWD per share a year, a dividend yield of 4.1%. The last ex-dividend date was Jul 28, 2026. The payout ratio is 25.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Savior Lifetec (4167)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Savior Lifetec it is 9.26 TWD per share (as of Nov 4, 2026), against a price of 18.40 TWD. It is the blended result of 15 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Savior Lifetec stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 4167 trades above its calculated fair value: price 18.40 TWD, fair value 9.26 TWD, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4167?
No. The price is what the market pays today (18.40 TWD); the fair value is what the company's own numbers justify (9.26 TWD). For Savior Lifetec the two are 9.14 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Savior Lifetec worth?
The market values Savior Lifetec at about 6.1B TWD (market capitalisation, as of Nov 4, 2026). Per share that is 18.40 TWD; our models calculate a fair value of 9.26 TWD per share.
What do the bullish and bearish scenarios say about 4167?
Our models span a range for Savior Lifetec: cautious scenario 7.82 TWD, base 9.26 TWD, optimistic 11.69 TWD per share (as of Nov 4, 2026, price 18.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4167?
Savior Lifetec trades at a price-to-earnings ratio of 6.3 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.26 TWD is built from several models across several years. Other multiples: P/B 1.6, P/S 5.4, EV/EBITDA 29.7.
How solid is the balance sheet of Savior Lifetec (4167)?
Balance-sheet figures for Savior Lifetec (as of Nov 4, 2026): return on equity 25.7%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 4167 from its 52-week high?
Savior Lifetec trades at 18.40 TWD, about 18% below its 52-week high of 22.40 TWD and 19% above the low of 15.43 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 9.26 TWD is for.
Which stocks are comparable to Savior Lifetec?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Savior Lifetec stock attractive at the current price?
The data as of Nov 4, 2026: price 18.40 TWD, calculated fair value 9.26 TWD (−50%), Quality Score 68/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4167 calculated?
We run Savior Lifetec through 15 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 9.26 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Savior Lifetec itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Savior Lifetec (4167)?
The closing price on Nov 6, 2026 was 18.40 TWD. Our model-based fair value is 9.26 TWD, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Savior Lifetec right now?
The price sits above even our optimistic bull case (11.69 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Savior Lifetec
How large is the market capitalisation of Savior Lifetec (4167)?
The market capitalisation of Savior Lifetec is 6.1B TWD (≈ $185M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Savior Lifetec (4167)?
The price-to-sales ratio of Savior Lifetec is 5.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Savior Lifetec (4167)?
Earnings per share at Savior Lifetec are 2.93 TWD (price ÷ EPS = P/E 6.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Savior Lifetec (4167)?
The dividend yield of Savior Lifetec is 4.1% (payout 25.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Savior Lifetec (4167)?
The net margin of Savior Lifetec is 91.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Savior Lifetec (4167)?
The return on equity (ROE) of Savior Lifetec is 25.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Savior Lifetec (4167)?
On an EBIT basis the return on assets of Savior Lifetec is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Savior Lifetec (4167)?
The operating margin of Savior Lifetec is 5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Savior Lifetec (4167)?
Revenue at Savior Lifetec is growing −14.8% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Savior Lifetec (4167)?
Earnings per share at Savior Lifetec are growing −76.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Savior Lifetec (4167) generate?
The free cash flow of Savior Lifetec is −164M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Savior Lifetec (4167) hold?
Savior Lifetec holds more cash than debt, 813M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Savior Lifetec in the live analysis
One click puts Savior Lifetec on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026